Login to Your Account



Other News To Note


Thursday, July 26, 2012
• Ligand Pharmaceuticals Inc., of San Diego, reported that the FDA granted priority review to its partner GlaxoSmithKline plc, of London, for the supplemental new drug application for Promacta (eltrombopag) to treat thrombocytopenia in adult patients with chronic hepatitis C. Promacta, marketed as Revolade outside the U.S., is approved in 89 countries to treat chronic immune thrombocytopenia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription